TEL AVIV, Israel, July 19, 2021 / PRNewswire / – Nasus Pharma, a private clinical-stage biopharmaceutical company developing a portfolio of powder-based intranasal (PBI) products to treat acute medical conditions and public health threats, today announced data from a collaborative in vitro study with the Central Virology Laboratory, Ministry of Health, Public Health Services, Sheba Medical Center, Tel Hashomer, Ramat gan, Israel, who demonstrated that the gel layer produced by Taffix® powder after administration of an infectious dose of the virus in tissue culture, effectively blocked 100% of the two new highly infectious Delta variants of the SARS-CoV-2 Delta virus. This is in addition to the recently announced effectiveness of Taffix under the same conditions against two additional variants: the Alpha (“British”) and beta (“South African”) variants as demonstrated by the qt PCR test of cells incubated with inoculated Taffix. with viruses.
The Delta variant is now the dominant strain of SARS-CoV 2 in more than 100 countries. It has been found to be significantly more contagious, transmissible in the early stages of the disease and replicates more quickly. The viral load found in a patient with the Delta strain was 1000 higher than the first strains identified during the outbreak of the pandemic1.
“These important results are consistent with previous in vitro studies performed with Taffix where 99.99% of SARS-CoV-2 viruses were blocked by Taffix2, 100% blockage of Alpha and Beta variants, as well as other viruses known to cause upper respiratory infections. It is important to note that these results are consistent with actual clinical experience with Taffix where the risk of contracting COVID was reduced by 78% following a “super spreader” event.3. These consistent results on several viral strains prove the robust non-specific activity against the transmission of several respiratory viruses, ”said Dr. Dalia Megiddo, CEO of Nasus Pharma. “The study results reconfirm the versatility of our technology against various respiratory viruses, including SARS-CoV-2 and its newer variants, as well as the potential of Taffix as an important additional layer of protection against infections. “
Udi Gilboa, Chairman of the Board of Directors of Nasus Pharma, added: “As new variants trigger a new wave of infections around the world, there is an urgent need for solutions that allow the safe resumption of economic and social activities. The changing dynamics of the virus and the continued emergence of additional mutations present a challenge to public health. Our new data demonstrates that Taffix can be useful in preventing the spread of these new variants in addition to all of the other recommended security measures. With the increasing use of Taffix around the world, we have learned how important an extra layer of protection is to facilitate a return to a safer normalcy. “
Taffix®, currently sold in over 25 countries across Europe, Latin America, Asia and Middle East was developed to create an acidic microenvironment in the nose that prevents viruses from entering and infecting nasal cells. It is now well established that the nose is the primary gateway to the body for airborne droplet virus infection, including SARS-VOC-2. Taffix® The powder creates a unique thin acidified gel over the nasal mucosa that lasts for 5 hours, greatly protecting nasal cells from inhaled viruses with mechanical and chemical protection. As such Taffix® may be an important new protective tool in addition to the multiple preventive measures taken today to prevent new variants of SARS-COV-2 from spreading further.
About Nasus Pharma:
Based on its unique microsphere technology, Nasus Pharma is developing a number of intranasal powder products to help patients in several acute emergency situations such as opioid overdose and anaphylactic shock.
Intranasal administration is most suitable for situations where rapid administration of the drug is required and offers multiple advantages such as rapid administration of the drug, ease of use, non-invasiveness and safety. The Nasus portfolio includes a number of programs: Intranasal Naloxone (pivotal study completed) and Intranasal Epinephrine (completed phase 2) as well as a number of preclinical POC programs.
2 Mann, Barbara J., et al. “TaffiX® nasal powder forms an effective barrier against SARS-CoV-2.” Biomedical Journal of Scientific and Technical Research 33.3 (2021): 25843-25845.
3Klang Shmuel, Megiddo Dalia, Lapidot Tair & Naparstek Yaakov (2021) Low pH hypromellose (Taffix) powder nasal spray could reduce rate of SARS-CoV-2 infection after mass gathering event in a community highly endemic: a prospective observational survey of open-label users, Expert Examination of anti-infective therapy, DOI: 10.1080 / 14787210.2021.1908127
SOURCE Nasus Pharma